Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype |
| |
| Affiliation: | 1. CHU of Nice, Hematology department, Cote D''Azur University, Nice Sophia Antipolis University, Nice, France;2. Saint-Louis Hospital, Hematology Department, Institut de Recherche Saint-Louis, Paris University, Paris, France;3. MLL Munich Leukemia Laboratory, Munich, Germany;4. CHU of Nice, Onco-hematology Laboratory, Cote D''Azur University, Nice Sophia Antipolis University, Nice, France;5. INSERM U1065, Mediterranean Center of Molecular Medecine, Cote D''Azur University, Nice, France;1. Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL;2. Division of Hematology-Oncology, Mayo Clinic, Rochester, MN;3. Division of Hematology-Oncology, Mayo Clinic, Phoenix, AZ;4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL;5. St. Barnabas Hospital, Bronx, NY;1. Department of Liberal Arts, Emory University, Atlanta, GA;2. Case Western Reserve University School of Medicine, Cleveland, OH;3. Katz School of Business, University of Pittsburgh, Pittsburgh, PA;4. Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;1. School of Medicine, Bahçeşehir University, Istanbul, Turkey;2. Myeloma Section, Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, Little Rock, AR;1. National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;2. Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;3. Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China;4. State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China |
| |
| Abstract: | BackgroundCore-binding factor acute myeloid leukemia (CBF AML) with recurrent genetic abnormalities inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/ CBFB-MYH11 are usually prognostically favorable but heterogeneous group and additional abnormalities change their prognosis.Materials and MethodsTo evaluate the impact of a complex karyotype on CBF AML prognosis, we included 24 patients with a median age of 56.4 years (23.2-83.3) and a median number of abnormalities of 5 (4-13).ResultsMedian follow-up was 110.4 months. Among patients with a primary clone, complete remission (CR) was reached in 66.7% of patients. 31.3% of patients experienced AML relapse with a median of 8.5 months. Median OS for transplanted patients was 80.7 versus 40.5 months for non-transplanted patients, excluding the 4 patients with early death. Among patients harboring AML with clonal evolution, CR was reached in 62.5% of patients. 50% of patients underwent allogeneic stem cell transplantation (ASCT). In these, median RFS was 19.3 versus 0 months in non-transplanted patients. Median OS seemed also longer in transplanted patients with 23.5 versus 2.95 months in non-transplanted.ConclusionUse of new treatment and tailored strategy based on measurable residual disease monitoring may now improve these results. However, these data allow us to reconsider the good prognosis historically associated with CBF patients despite of karyotype and the place of ASCT in the strategy. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
